

SPRINGER  
REFERENCE

Franz J. Hock  
Michael R. Gralinski  
*Editors*

# Drug Discovery and Evaluation: Methods in Clinical Pharmacology

*Second Edition*

---

# Contents

## Volume 1

|                                                                                                                           |            |
|---------------------------------------------------------------------------------------------------------------------------|------------|
| <b>Part I Human Studies in Clinical Pharmacology</b>                                                                      | <b>1</b>   |
| <b>1 Methodologies of Safety Assessment in Clinical Pharmacology</b>                                                      | <b>3</b>   |
| Werner Seiz                                                                                                               |            |
| <b>2 Pharmacodynamic Evaluation: Cardiovascular Methodologies</b>                                                         | <b>19</b>  |
| Ivana I. Vranic                                                                                                           |            |
| <b>3 Characterization of Cardiac Electrophysiology Including ECG-Analysis</b>                                             | <b>51</b>  |
| Ivana I. Vranic                                                                                                           |            |
| <b>4 Pharmacodynamic Evaluation: CNS Methodologies</b>                                                                    | <b>81</b>  |
| Lynne Hughes, Marie Trad, Stacey Boyer, Deborah Lee, and Wei Yin                                                          |            |
| <b>5 Pharmacodynamic Evaluation: Pain Methodologies</b>                                                                   | <b>95</b>  |
| Pieter Siebenga, Pieter Okkerse, Guido van Amerongen, Robert Jan Doll, Alex Mentink, Justin Hay, and Geert Jan Groeneveld |            |
| <b>6 Pharmacodynamic Evaluation: Drug Dependency and Addiction</b>                                                        | <b>127</b> |
| V. Tenev and M. Nikolova                                                                                                  |            |
| <b>7 Pharmacodynamic Evaluation: Ocular Pharmacology</b>                                                                  | <b>163</b> |
| Najam A. Sharif                                                                                                           |            |
| <b>8 Clinical Pharmacology of Tinnitus: Design and Evaluation</b>                                                         | <b>209</b> |
| Agnieszka J. Szczeppek                                                                                                    |            |
| <b>9 Clinical Aspects in Sleep Disorders and Apnea</b>                                                                    | <b>223</b> |
| Thomas Penzel and Ingo Fietze                                                                                             |            |

|           |                                                                                                                 |     |
|-----------|-----------------------------------------------------------------------------------------------------------------|-----|
| <b>10</b> | <b>Pharmacodynamic Evaluation: Diabetic Methodologies</b> . . .                                                 | 243 |
|           | Juergen Sandow                                                                                                  |     |
| <b>11</b> | <b>Pharmacodynamic Evaluation: Gastroenterology</b> . . . . .                                                   | 263 |
|           | Petar Nikolov, Georgi Banishki, and Milena Nikolova-Vlahova                                                     |     |
| <b>12</b> | <b>Pharmacodynamic Evaluation: Endocrinology</b> . . . . .                                                      | 283 |
|           | Michael A. B. Naafs                                                                                             |     |
| <b>13</b> | <b>Pharmacodynamic Evaluation: Dermatology</b> . . . . .                                                        | 299 |
|           | Liora Bik and Hok Bing Thio                                                                                     |     |
| <b>14</b> | <b>Pharmacodynamic Evaluation: Inflammation/<br/>Immunology</b> . . . . .                                       | 317 |
|           | Jörg Schüttrumpf and Matthias Germer                                                                            |     |
| <b>15</b> | <b>Pharmacodynamic Evaluation: Infectious Diseases</b> . . . . .                                                | 325 |
|           | Smita Bhuyan, Sebastian Felgner, Dino Kocijancic, and<br>Vinay Pawar                                            |     |
| <b>16</b> | <b>Role of Clinical Pharmacodynamics Studies in the Era<br/>of Precision Medicines Against Cancer</b> . . . . . | 343 |
|           | Fatih M. Uckun and Sanjive Qazi                                                                                 |     |
| <b>17</b> | <b>Pharmacodynamic Evaluation: Gene Therapy</b> . . . . .                                                       | 361 |
|           | Nicolas Grandchamp                                                                                              |     |
| <b>18</b> | <b>Pharmacological Therapy in Inborn Errors of<br/>Metabolism</b> . . . . .                                     | 385 |
|           | Anibh M. Das and Sabine Illsinger                                                                               |     |
| <b>19</b> | <b>Clinical Studies in Infants (Pediatric Pharmacology)</b> . . . . .                                           | 401 |
|           | Karel Allegaert                                                                                                 |     |
| <b>20</b> | <b>Clinical Studies in Geriatric Population</b> . . . . .                                                       | 417 |
|           | Petra A. Thürmann                                                                                               |     |
| <b>21</b> | <b>Personalized Medicine</b> . . . . .                                                                          | 425 |
|           | Federico Goodsaid, Felix Frueh, and Michael E. Bureczynski                                                      |     |
| <b>22</b> | <b>Noninvasive Methodology (NMR)</b> . . . . .                                                                  | 439 |
|           | Mitul A. Mehta                                                                                                  |     |
| <b>23</b> | <b>Traditional Chinese Medicine and Clinical<br/>Pharmacology</b> . . . . .                                     | 455 |
|           | Anita Chen Marshall                                                                                             |     |
| <b>24</b> | <b>Pharmacodynamic Evaluation: Herbal Medicine</b> . . . . .                                                    | 483 |
|           | Gulam Mohammed Husain, Mohammad Ahmed Khan,<br>Mohd Urooj, and Munawwar Husain Kazmi                            |     |
| <b>25</b> | <b>Chronopharmacology in Drug Development</b> . . . . .                                                         | 499 |
|           | Björn Lemmer                                                                                                    |     |
| <b>26</b> | <b>Space Pharmacology: How Space Affects Pharmacology</b> . . .                                                 | 519 |
|           | Virginia Wotring                                                                                                |     |

|           |                                                                                                                |     |
|-----------|----------------------------------------------------------------------------------------------------------------|-----|
| <b>27</b> | <b>Nanotechnology in Medicine</b> .....                                                                        | 533 |
|           | M. Nikolova, R. Slavchov, and G. Nikolova                                                                      |     |
| <b>28</b> | <b>Gender Differences in Drug Therapy</b> .....                                                                | 547 |
|           | Anthony G. Fenech and Vanessa Petroni Magri                                                                    |     |
| <b>29</b> | <b>Methodologies of PD Assessment: Scales</b> .....                                                            | 571 |
|           | Roman Görtelmeyer                                                                                              |     |
| <b>30</b> | <b>Methods in Clinical Pharmacology</b> .....                                                                  | 593 |
|           | Lorraine M. Rusch and Clayton Dehn                                                                             |     |
| <b>31</b> | <b>Pharmacodynamic Drug–Drug Interactions</b> .....                                                            | 603 |
|           | Ming Zheng                                                                                                     |     |
| <b>32</b> | <b>Medical Devices: Definition and Clinical Testing</b> .....                                                  | 613 |
|           | Lea Wettlaufer and Daniela Penn                                                                                |     |
| <b>33</b> | <b>Food Supplements: Definition and Classification</b> .....                                                   | 625 |
|           | Evelyn Breitweg-Lehmann, Birgit Liebscher, and<br>Carolin Bendadani                                            |     |
| <b>34</b> | <b>Stem Cell Therapy</b> .....                                                                                 | 637 |
|           | Nina Graffmann, Lucas-Sebastian Spitzhorn, Soraia Martins,<br>Md Shaifur Rahman, Lisa Nguyen, and James Adjaye |     |

## Volume 2

|                |                                                                                                                |            |
|----------------|----------------------------------------------------------------------------------------------------------------|------------|
| <b>Part II</b> | <b>Clinical Pharmacokinetics</b> .....                                                                         | <b>669</b> |
| <b>35</b>      | <b>Dose Finding in Single Dose Studies by Allometric<br/>Scaling</b> .....                                     | 671        |
|                | Zheng Lu, Rüdiger Kaspera, Yoichi Naritomi, and Tianli Wang                                                    |            |
| <b>36</b>      | <b>Pharmacokinetic Aspects of Multiple Dose Studies</b> .....                                                  | 683        |
|                | Steven G. Woolfrey and James Gilmour Morrison                                                                  |            |
| <b>37</b>      | <b>Dose Linearity and Proportionality</b> .....                                                                | 695        |
|                | Tanja Eisenblaetter, Lenore Teichert, Ronald Burnette, and<br>Paul Hutson                                      |            |
| <b>38</b>      | <b>Effects of Food Intake</b> .....                                                                            | 715        |
|                | Teodora Handjieva-Darlenska                                                                                    |            |
| <b>39</b>      | <b>Special Populations: Profiling the Effect of Obesity on<br/>Drug Disposition and Pharmacodynamics</b> ..... | 723        |
|                | Kenneth T. Moore                                                                                               |            |
| <b>40</b>      | <b>Special Populations: Renal<br/>Impairment</b> .....                                                         | 749        |
|                | Gerard Sanderink and Andreas Kovar                                                                             |            |
| <b>41</b>      | <b>Special Populations: Influence of Hepatic<br/>Impairment</b> .....                                          | 759        |
|                | Gerard Sanderink and Andreas Kovar                                                                             |            |

|           |                                                                                                        |      |
|-----------|--------------------------------------------------------------------------------------------------------|------|
| <b>42</b> | <b>Special Populations: Protein Binding Aspects</b> .....                                              | 765  |
|           | Italo Poggesi                                                                                          |      |
| <b>43</b> | <b>The Human ADME Study</b> .....                                                                      | 773  |
|           | Andrew McEwen                                                                                          |      |
| <b>44</b> | <b>Synthesis of Radiolabelled Compounds for Clinical Studies</b> .....                                 | 807  |
|           | Jens Atzrodt, Volker Derdau, and Claudia Loewe                                                         |      |
| <b>45</b> | <b>Drug–Drug Interaction Studies</b> .....                                                             | 827  |
|           | Peter Stopfer                                                                                          |      |
| <b>46</b> | <b>In Vitro/In Vivo Correlation for Drug-Drug Interactions</b> .....                                   | 847  |
|           | Jan Wahlstrom and Larry Wienkers                                                                       |      |
| <b>47</b> | <b>Specific Studies for Formulation Development</b> .....                                              | 867  |
|           | Roland Wesch                                                                                           |      |
| <b>48</b> | <b>Absolute and Relative Bioavailability</b> .....                                                     | 879  |
|           | Khaled Abo-EL-Sooud                                                                                    |      |
| <b>49</b> | <b>Bioequivalence</b> .....                                                                            | 887  |
|           | Henning H. Blume                                                                                       |      |
| <b>50</b> | <b>Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamics in Clinical Pharmacology</b> ..... | 903  |
|           | Daniel F. B. Wright, Chihiro Hasegawa, and Hesham S. Al-Sallami                                        |      |
| <b>51</b> | <b>In Silico Drug Repositioning Using Omics Data: The Potential and Pitfalls</b> .....                 | 929  |
|           | Enya E. Scanlon and Jaïne K. Blayney                                                                   |      |
| <b>52</b> | <b>Toxicokinetics and Safety Ratios</b> .....                                                          | 949  |
|           | Ferdi Sombogaard                                                                                       |      |
| <b>53</b> | <b>In/In Vivo Correlation for Transporters</b> .....                                                   | 957  |
|           | Sandra Cvijic                                                                                          |      |
| <b>54</b> | <b>Relevance of Transporters in Clinical Studies</b> .....                                             | 989  |
|           | Bruno Hagenbuch                                                                                        |      |
| <b>55</b> | <b>Role of Clinical Pharmacokinetics Studies in Contemporary Oncology Drug Development</b> .....       | 1005 |
|           | Fatih M. Uckun and Sanjive Qazi                                                                        |      |
| <b>56</b> | <b>Pharmacogenomics in and Its Influence on Pharmacokinetics</b> .....                                 | 1019 |
|           | Guy Montay, Jochen Maas, and Roland Wesch                                                              |      |
| <b>57</b> | <b>PK/PD Approaches</b> .....                                                                          | 1047 |
|           | Yichao Yu, Diether Ruppel, Willi Weber, and Hartmut Derendorf                                          |      |

---

|                 |                                                                        |             |
|-----------------|------------------------------------------------------------------------|-------------|
| <b>58</b>       | <b>General Principles of Pharmacovigilance in Clinical Development</b> | <b>1071</b> |
|                 | Rainer Heissing and Anne-Ruth van Troostenburg                         |             |
| <b>Part III</b> | <b>Regulations</b>                                                     | <b>1083</b> |
| <b>59</b>       | <b>Regulatory Guidance: ICH, EMA, FDA</b>                              | <b>1085</b> |
|                 | Gerd Bode                                                              |             |
| <b>60</b>       | <b>Clinical Quality Management System</b>                              | <b>1139</b> |
|                 | Beat Widler                                                            |             |
| <b>61</b>       | <b>Future of Regulatory Safety Assessments</b>                         | <b>1145</b> |
|                 | Gerd Bode and Petra Starck-Lantova                                     |             |
| <b>Index</b>    |                                                                        | <b>1169</b> |